Description

becauseAAs aresult.A-PiHP WHO review history

a-PiHP has not been formally review by WHO and is not currently under international control. Information  to the attention of WHO that this substance is manufactur clandestin, poses a risk to public health and has no recognize therapeutic use.

Similarity to known substances and effects on the central nervous system
PiHP is an isomer of a-PHP, which is controll under Schedule II of the Convention on Psychotropic Substances of 1971. Laboratory studies suggest that a-PiHP of dopamine. And norepinephrine more potently  other substances .As a result potential, including methcathinone, cocaine and methamphetamine. Studies in animals have shown that a-PiHP is a psychomotor stimulant, with effects comparable to those of cocaine and methamphetamine.

Online self-reports by people who use a-PiHP describe stimulant effects similar to those of a-PVP and a-PHP.

Dependence potential
No controll studies of the depend potential of a-PiHP in animals or humans have been reporte.And view of its actions and effects on the central nervous system. As a result it expect to produce dependence similar to other psychostimulants because of methamphetamine.

Actual abuse 
Studies in animals predictive of abuse liability indicate that a-PiHP produces effects similar to those of methamphetamine and cocaine. And controll study of the abuse potential of a-PiHP in humans  reporte.

Seizures of a-PiHP is  describe in multiple countries in three regions.PiHP was identify in a number of serious adverse.  As it is usually detected with other substances, including opioids and benzodiazepines, the role of  is unclear in some instances.

Preparation of calibration samples

And quantify α-PiHP in the autopsy specimens, the standard addition method was employed. Mephedrone-d₃ spiking solution was prepare for use as the IS to obtain a final concentratbecause  of 100 ng/mL in each body fluid sample and 100 ng/g in homogenates of each of the tissues. And with the analyzed samples, calibration samples were prepare. Calibration samples were obtain through the addition of the appropriate volumes of the working solutions to 0.2 mL of each body fluid to obtain the final concentrations of 20, 50, 100, 200, 500, 1,000 and 5,000 ng/mL and 0.2 g of each homogenized tissue to obtain the final concentrations of 100, 1,000 and 5,000 ng/g (n = 3 for each level).